Navigation Links
Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention

BEVERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek Pharmaceuticals Corporation announced today the presentation of positive Phase 2 clinical data demonstrating the safety of INO-1001 as well as the potential for INO-1001 as a preventative agent for cardiac reperfusion injury. The study was conducted in subjects with acute ST-elevated myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. The presentation was made in a poster session at the American College of Cardiology (ACC) 56th Annual Scientific Session in New Orleans, Louisiana. INO-1001 is an inhibitor of poly(ADP-Ribose) polymerase (PARP), a nuclear enzyme that directs the repair of damaged DNA via the activation and recruitment of DNA repair enzymes and is being studied as a treatment for certain acute cardiovascular conditions and cancer. Additionally, PARP inhibition shows promise in inflammatory disorders. PARP's role in the inflammatory response may result from its ability to potentiate the activity of key inflammatory transcription factors (NF-kappaB and AP-1).

"Whereas advances in pharmacologic and mechanical reperfusion therapy have improved the outcomes of patients with STEMI, reperfusion injury, which is associated with severe damage to the cardiac tissue, is a significant complication that has no current safe and effective treatment options," commented Dr. Andrew Salzman, Inotek's President and CEO. "These Phase 2 data provide further support for our PARP inhibitor program in cardiovascular disease. These results combined with existing preclinical data suggest that INO-1001 produces significant PARP inhibition and has the potential to protect cardiac tissue from damage."

Researchers from the Brigham and Women's TIMI Study Group and Inotek Pharmaceuticals reported that plasma from patients treated with INO-1001 suppressed ex vivo PARP activation. This effect was observed up to 24 hours following drug admi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:9/19/2014)... 19, 2014 Larry J. Merlo , President ... will speak before the National Press Club in ... recent move to stop selling tobacco products and its leadership ... health. "Dramatic changes in our health care system ... government," Merlo has said. "CVS Health has a truly unique ...
(Date:9/19/2014)... SOUTH EASTON, Mass. , Sept. 19, 2014 ... the "Company") today announced it has received and ... throughput Barozyme HT48 instruments and has begun to ... believes the first instrument will be ready for ... will be built and released at a rate ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. ... Inspire therapy continues to grow, with the publication of ... on-line in Otolaryngology – Head and Neck ... a worsening of both objective and subjective measures of ... attribute Inspire therapy for the reduction in obstructive sleep ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the ... commercialization of its proprietary stent platform technology, today announced that ... ended September 30, 2011 with the U.S. Securities and Exchange ... Year-to-Date Highlights Year-to-date shipment ...
... The new harder to crush version of OxyContin® has ... research revealed at a conference of law enforcement officers ... Prevention (CDC) announced that every day 100 people die ... prescription opioid pain relievers. A new formulation of the ...
Cached Medicine Technology:InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 2InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 3InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 4InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 5InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 6InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 7InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 8InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 9New OxyContin® Has Lower Street Price Than Old Crushable Formulation 2
(Date:9/20/2014)... (PRWEB) September 20, 2014 MarijuanaDoctors.com ... successful showing at the PAIN Week conference that ... Hotel and Casino in Las Vegas from September ... primarily attended PAIN Week in the hopes of ... a viable and legitimate tool to treat chronic ...
(Date:9/19/2014)... Nearly 780 Risperdal lawsuits are moving forward ... meeting took place to discuss the next steps in ... court’s mass tort program. Attorneys for the plaintiffs and ... the Complex Litigation Center in Philadelphia’s City Hall where ... Risperdal lawsuits filed against Johnson & Johnson and its ...
(Date:9/19/2014)... 19, 2014 “Copay coupons,” a drug ... brand drugs among patients with prescription drug coverage, may ... a new report from the Department of Health ... Federal anti-kickback laws prohibit suppliers from offering side-payments to ... federal government. , The report highlights that two recent ...
(Date:9/19/2014)... KS (PRWEB) September 19, 2014 Unbound ... responding to families in regions of the Philippines being affected ... , More than 1,060 families evacuated to the nearest public ... Fung-Wong brought heavy rain and gusty winds to portions of ... causing heavy flooding. Some homes filled with more than 10 ...
(Date:9/19/2014)... -- As kids transition from elementary to middle school, ... a recent study. But the researchers studying ... verbal and physical bullying declines as students get older. ... strategies must address all types of bullying as well ... researchers said. The study was published recently in ...
Breaking Medicine News(10 mins):Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2
... ... Point Solutions has been awarded the prestigious Gold certification from Cisco ... specialization. The Certification recognizes High Point,s expert level of achievement ... Communication, and Data Center. Gold Certified Partners are considered extensions of ...
... Biotherapeutics Inc. ("GENova") clarified today information disseminated in previous ... portfolio. , GENova owns the rights to a range ... all of them. The patents have not yet been ... been brought to GENova,s attention that previous releases were ...
... ... chiropractor, has taken over Optimal Body Chiropractic within Tuscan Sun Massage & Wellness in ... all ages by enhancing the relationship between the spine, nervous system, and the rest ... ...
... Public Health has been awarded $18.4 million by the ... Department of Defense to establish an Extremity Trauma Clinical ... coordinating center for the Consortium that includes a network ... several major military treatment centers and the U.S. Army ...
... young adults with acoustic neuromas , FRIDAY, Sept. 11 (HealthDay ... her mother,s voice or the sound of a dog barking. ... she had neurofibromatosis type 2 (NF2), a condition characterized by ... damaged the eighth cranial nerve in one ear. , The ...
... Sept. 11 United American Healthcare Corporation (Nasdaq: UAHC ... fourth fiscal quarter and full year ended June 30, 2009 on ... to file its Form 10-K for the period ended June 30, ... in compliance with applicable regulations. In addition, the Company announced ...
Cached Medicine News:Health News:High Point Solutions has Been Awarded the Prestigious Gold Certification from Cisco Systems 2Health News:GENova issues clarifying press release 2Health News:Chiropractic Helps Strengthen Immune System and Prevent Sickness 2Health News:JHSPH to lead extremity trauma clinical research consortium 2Health News:JHSPH to lead extremity trauma clinical research consortium 3Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 2Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 3Health News:United American Healthcare Corporation Announces Release Date for Fiscal 2009 Fourth Quarter and Full Year Results 2